June 10, 2020
Valerie Guild was Founder and President of the non-profit organization AIM at Melanoma, and served as a patient advocate on ECOG-ACRIN’s Melanoma Committee for over ten years.
June 9, 2020
De-escalation is an effort to reduce the intensity of treatment without sacrificing efficacy. This issue covers several de-escalation trials: DECREASE, CompassHER2 pCR, and E3311.
June 8, 2020
This study is evaluating whether lower doses of chemoradiation will be able to effectively treat early-stage anal squamous cell carcinoma while also decreasing side effects.
June 7, 2020
The purpose of this study is to find out if some patients with early-stage HER2 positive breast cancer can safely be treated with less chemotherapy than is generally used.
June 6, 2020
This trial is comparing chemotherapy and radiation to chemotherapy and radiation plus an immunotherapy drug.
June 6, 2020
This study showed that surgery followed by low-dose radiation alone led to very good outcomes, similar to surgery with standard-dose radiation, preserving patients’ throat function and potentially sparing them unnecessary side effects.